Kura Oncology, INC Form 4 insider transactions

Director Diane Parks was granted 35,000 stock options in Kura Oncology, Inc. with an exercise price of $8.77.

Director Michael Vasconcelles was granted 35,000 stock options in Kura Oncology, Inc. as part of a standard equity compensation arrangement.

Director Faheem Hasnain was granted an option to purchase 35,000 shares of Kura Oncology common stock.

Director Helen Collins was granted an option to purchase 35,000 shares of Kura Oncology common stock at an exercise price of $8.77.

Director Carol Schafer was granted 35,000 stock options in Kura Oncology, Inc. as part of a standard equity compensation package.

Director Mary Szela was granted 35,000 stock options in Kura Oncology, Inc. as disclosed in a recent SEC Form 4 filing.

Director Thomas Malley was granted 35,000 stock options in Kura Oncology, Inc. as part of a standard equity compensation arrangement.

Chief Commercial Officer Brian Powl sold 10,000 shares of Kura Oncology common stock pursuant to a pre-arranged 10b5-1 trading plan.

Kura Oncology's Chief Commercial Officer, Brian T. Powl, reported transactions involving company common stock, including purchases under an employee stock purchase plan and sales executed via a Rule 10b5-1 trading plan.

Kura Oncology's Chief Operating Officer, Kathleen Ford, acquired 2,257 shares of common stock through an employee stock purchase plan on May 19, 2026, as part of a pre-arranged trading plan.

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, acquired 2,256 shares of common stock through an Employee Stock Purchase Plan executed under a Rule 10b5-1 trading plan.

Kura Oncology's President and CEO, Troy Edward Wilson, exercised 6,103 stock options at $6.15 per share.

Kura Oncology Director Thomas Malley exercised 10,000 stock options at $3.12 per share, increasing his direct holdings.

Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold 6,414 shares of common stock on January 27, 2026, to cover tax liabilities from RSU vesting.

Kura Oncology's Chief Operating Officer, Kathleen Ford, sold 1,813 shares of common stock to cover tax obligations related to RSU vesting.

Kura Oncology's Chief Medical Officer, Mollie Leoni, has filed a Form 4 detailing planned future sales of common stock to cover tax obligations related to vested restricted stock units.

Kura Oncology's SVP of Finance and Accounting, Thomas James Doyle, sold 7,142 shares of common stock to cover tax obligations related to vested restricted stock units.

Kura Oncology's Chief Scientific Officer, Francis Burrows, sold 1,311 shares of common stock at $8.4607 per share to cover tax obligations related to RSU vesting.

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, sold common stock on January 27, 2026, to cover tax obligations related to vested restricted stock units.

Kura Oncology's Chief Medical Officer, Mollie Leoni, was granted 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock.

Kura Oncology's SVP of Finance & Accounting, Thomas James Doyle, received grants of Restricted Stock Units and stock options, increasing his beneficial ownership.

Kura Oncology's President and CEO, Troy Edward Wilson, was granted 1,120,000 stock options with an exercise price of $10.335, vesting over 48 months.

Kura Oncology's Chief Operating Officer, Kathleen Ford, was granted 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock.

Kura Oncology's Chief Scientific Officer, Francis Burrows, was granted 185,000 stock options with an exercise price of $10.335.

Kura Oncology's Chief Commercial Officer, Brian T. Powl, received grants of 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock.

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, was granted 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock.

Kura Oncology's Chief Scientific Officer, Francis Burrows, exercised stock options and subsequently sold a portion of the acquired shares to cover tax liabilities.

Kura Oncology Director Faheem Hasnain reported the acquisition and subsequent sale of 10,000 common shares under a pre-arranged Rule 10b5-1 plan.

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, acquired shares through PSU vesting and subsequently sold a portion to cover tax obligations.

Kura Oncology's President and CEO, Troy Edward Wilson, acquired 182,500 shares of common stock through the vesting of performance-based restricted stock units after a development milestone was met.